Navigation Links
Amarin Regains Compliance With Nasdaq Listing Requirements
Date:2/11/2008

LONDON, February 11 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that it has received notification from The Nasdaq Stock Market that the Company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, pursuant to Nasdaq Marketplace Rule 4320(e)(2)(E)(ii). In the notification, Nasdaq advised that the Company has regained compliance with all continued listing requirements and that this matter is now closed.

Thomas Lynch, Chairman and Chief Executive Officer, commented "We are pleased to receive this notification, as continued listing on Nasdaq is an integral part of our plans to build shareholder value, having recently expanded our pipeline and strengthened our management team."

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. In accordance with customary Nasdaq practice, following Amarin's reverse stock split, which took effect from January 18, 2008, a "D" will be appended to Amarin's Nasdaq ticker symbol for a period of 20 trading days and during that period Amarin's Nasdaq ticker symbol will appear as "AMRND". The ticker symbol will return to "AMRN" on February 19, 2008.


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
2. Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntingtons Disease Program
3. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
4. Adaptis Compliance Officer Earns Advanced Certificate
5. Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008
6. Mitchell Medical and Jopari Solutions Team up to Offer eBilling Compliance Services to Automobile Property & Casualty Insurance Carriers to Meet New Minnesota Requirements
7. Sharon McCudden Named KePRO Director of Business Process Improvement & Compliance
8. Vendormate Storms into 2008 with Major Milestones for Hospital Vendor Compliance
9. Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing
10. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
11. GetWellNetwork Offers Comprehensive Education Package Enabling Hospitals to Meet Compliance Requirements for Patient Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream ... procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a variety ... , dermaka cream is very effective for bruising and causes a rapid resolution ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan ... the South Lamar location as of July 13, 2016. , Dr. Daulat earned her ... medical student, she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: